An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma

Completed · Phase 1

Conditions studied: Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

In brief

The purpose of this study is to predict responses to Erbitux as a single agent in patients with Non Small Cell Lung Cancer

Key facts

Study ID

NCT00207116

Run by

Eli Lilly and Company

People needed

120

Starts

2005-09-01

Expected to finish

2006-03-01

Last updated by the study team

2015-10-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Measurable disease tumor available for biopsies
• Life expectancy of at least 3 months

You may not qualify if…

• Known or documented brain metastases prior to Cetuximab therapy

Where it is running

• Local Institution — Newark, Delaware, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.